J Clin Med
High-Dose Aflibercept for Refractory AMD
Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K.
This study evaluated the efficacy of intravitreal aflibercept 8 mg in patients with age-related macular degeneration who had previously received anti-VEGF treatments. Results demonstrated meaningful anatomical and visual improvements, with a high proportion of eyes achieving fluid resolution on OCT. The findings suggest that high-dose aflibercept may be a valuable option for patients with persistent or refractory disease, potentially extending dosing intervals while maintaining efficacy.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
- • Aflibercept 8 mg: Long-Term Outcomes in PULSAR
- • Plain Language Summary of Publication of the 48-Week Results From PULSAR
- • High-Dose Aflibercept for Refractory AMD
